Coronavirus disease 2019 (COVID-19) is a novel and lethal infectious disease, posing a threat to global health security. The number of cases has increased rapidly, but no data concerning kidney transplant (KTx) recipients infected with COVID-19 are available. To present the epidemiological, clinical, and therapeutic characteristics of KTx recipients infected with COVID-19, we report on a case series of five patients who were confirmed as having COVID-19 through nucleic acid testing (NAT) from January 1, 2020 to February 28, 2020. The most common symptoms on admission to hospital were fever (five patients, 100%), cough (five patients, 100%), myalgia or fatigue (three patients, 60%), and sputum production (three patients, 60%); serum creatinine or urea nitrogen levels were slightly higher than those before symptom onset. Four patients received a reduced dose of maintenance immunosuppressive therapy during hospitalization. As of March 4, 2020 NAT was negative for COVID-19 in three patients twice in succession, and their computed tomography scans showed improved images. Although greater patient numbers and long-term follow-up data are needed, our series demonstrates that mild COVID-19 infection in KTx recipients can be managed using symptomatic support therapy combined with adjusted maintenance immunosuppressive therapy.

2019冠状病毒病（COVID-19）是一种新型致命传染病，对全球卫生安全构成威胁。病例数量迅速增加，但没有关于感染 COVID-19 的肾移植 (KTx) 受者的数据。为了介绍感染了 COVID-19 的 KTx 接受者的流行病学、临床和治疗特征，我们报告了 2020 年 1 月 1 日至 2 月期间通过核酸检测 (NAT) 确认患有 COVID-19 的 5 名患者的病例系列2020年12月28日。入院时最常见的症状是发烧（5名患者，100%）、咳嗽（5名患者，100%）、肌痛或疲劳（3名患者，60%）和咳痰（3名患者，60%） %); 血清肌酐或尿素氮水平略高于症状出现前。四名患者在住院期间接受了减少剂量的维持免疫抑制治疗。截至 2020 年 3 月 4 日，三名患者的 NAT 检测结果连续两次呈 COVID-19 阴性，他们的计算机断层扫描显示图像有所改善。尽管需要更多的患者数量和长期随访数据，但我们的系列研究表明，可以使用对症支持治疗结合调整后的维持性免疫抑制治疗来控制 KTx 接受者的轻度 COVID-19 感染。